Compare United States Copper Index Fund (CPER) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Vertex Pharmaceuticals Incorporated — how do they compare? United States Copper Index Fund trades at $40.31 (market cap $708.28M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 180.1× United States Copper Index Fund's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 49 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CPER | VRTX | |
|---|---|---|
Market Cap | $708.28M | $127.55B |
Volume | 339,046 | 1,487,944 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $557.96 |
52-Week Low | $30.27 | $407.37 |
Typical Hold Time | 49 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER trades at $40.31, up 1.26% on the day, but technical indicators signal a bearish trend with moving averages and the ADX pointing lower. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. Recent news highlights strong copper demand driven by AI infrastructure, though some reports note price volatility and miner underperformance, creating a mixed backdrop for copper-related equities.
The outlook for CPER is cautious due to bearish technicals and lack of clear fundamental data. Positive copper demand trends from AI and potential supply constraints offer long-term opportunity, but near-term price pressure on miners and absence of company-specific financials elevate risk. Investors require current earnings and valuation metrics to gauge intrinsic value amid sector volatility.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
